Tesaro Inc

Tesaro — Investor Presentation (March 2016)

66 slides from Tesaro's investor presentation, Mar 16, 2016

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S

  2. Slide 2: The Right Medicine for the Right Patient

    The Right Medicine for the Right Patient Global Product Reach Oncology Focus, Small and Large Molecule Approaches Our Vision TESARO: TESARO Will Be a Leading Oncology-Focused Biopharmaceutical Company

  3. Slide 3: Strong Financial and Strategic Position

    Strong Financial and Strategic Position TESARO: First Commercial Product Launched Portfolio Addresses Large Markets Balanced Product Pipeline Strong Financial Position Proven Management Team CINV: >$1B Ovarian: $4B Breast: $1B Several Programs, Early to Late Stage, Small Molecules & Biologics ~$230M

  4. Slide 4: A Balanced Portfolio of Product Candidates

    A Balanced Portfolio of Product Candidates mAb: Monoclonal antibody * In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups ** In collaboration with the Hoosier Cancer Research Network *** In collaboration with SARC, the Sarcoma Alliance for Research through C

  5. Slide 5: 2016 Goals

    2016 Goals NDA: New Drug Application MAA: Marketing Authorization Application mAb: Monoclonal Antibody IV: Intravenous EMA: European Medicines Agency IND: Investigational New Drug application Continue to execute on the U.S. VARUBI® commercial launch Submit the oral rolapitant MAA to the EMA in Q2 20

  6. Slide 6: VARUBI (rolapitant) CINV Opportunity

    VARUBI® (rolapitant) CINV Opportunity

  7. Slide 7: VARUBI: TESARO's First Marketed Product

    Approved by FDA on September 1, 2015 1 Provides protection from CINV for the full delayed risk period (25-120 hours) 2 Single oral dose administration just prior to chemotherapy 6 Included in NCCN® Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus for MEC and HEC 3 No dose adju

  8. Slide 8: Despite Available Therapies, Significant Unmet Need Remains in CINV

    Despite Available Therapies, Significant Unmet Need Remains in CINV 1 For selected patients as appropriate. 2 J Support Oncol 2004;2(suppl 1):1-12. HCPs: Healthcare Providers. Start before chemotherapy Serotonin (5-HT3) receptor antagonist AND Steroid AND Neurokinin 1 antagonist NCCN Guidelines® Ver

  9. Slide 9: Mechanisms of CINV

    Mechanisms of CINV Neurokinin = NK Serotonin = 5-HT Chemotherapy Peripheral Central Substance P released Substance P binds NK-1R in Dorsal Vagal Complex (DVC) DVC coordinates incoming emetogenic stimuli from brain and periphery Signals through Vagal Afferent to Brain Serotonin binds 5-HT3R Enterochr

  10. Slide 10: CINV is Ranked Among the Worst Side Effects of Chemotherapy

    CINV 1: little to no acute or delayed nausea or vomiting. CINV 2: complete acute control; moderate delayed nausea, no vomiting. CINV 3: moderate delayed nausea, severe delayed vomiting. CINV 4: Acute nausea and vomiting; moderate delayed nausea, severe vomiting. CINV 5: acute nausea and vomiting; mo

  11. Slide 11: The Phases of CINV

    The Phases of CINV Grunberg SM. J Support Oncol. 2004;2(1 Suppl 1):1-10. Timing of Three Distinct Phases of CINV Day -1 Day 0 Day 1 Day 5 Anticipatory Acute Delayed Chemotherapy Initiation Day 2 Day 3 Day 4 Treatment: Behavioral Treatment: Pharmacologic NK-1 RA 5HT-3 RA Chemotherapy-induced Nausea &

  12. Slide 12: Phase 3 Trials Demonstrate Significant Patient Need in Delayed Phase

    Phase 3 Trials Demonstrate Significant Patient Need, Particularly in the Delayed Phase Results of Phase 3 Trials of NK-1 RAs % of patients who vomited or required rescue medication 24–120 hours following chemotherapy, despite receiving a 5HT-3 receptor antagonist and corticosteroid treatment 30–53%

  13. Slide 13: VARUBI (rolapitant) Launch Update

    VARUBI® (rolapitant) Launch Update

  14. Slide 14: Commercial Launch Update

    Commercial Launch Update Data as of February 29, 2016; IOD: In-office dispensing; RA: receptor antagonist 1 Source: Company estimates; wholesaler and specialty pharmacy data 2 Source: IMS DDD data analysis and Company estimates 3 Source: Managed Markets Insight & Technology, LLC and Company estimate

  15. Slide 15: Brand Vision

    Brand Vision Ensure All Eligible Patients Receive VARUBI® Proactively, Thereby Protecting Them During the Delayed CINV Period VARUBI®: Grow NK-1 Market Deliver a Compelling Differentiation Build Strong Customer Engagement Optimize Market Access

  16. Slide 16: Brand Strategy to Drive Growth

    Brand Strategy to Drive Growth VARUBI®: Establish Oral, Take Share Establish IV, Take Share Grow NK-1 Market Opportunity Goal to Reach the Patient at Time of First Chemotherapy Dose Year 1 Year 2 Year 3 Year 4 Volume Oral IV

  17. Slide 17: Large U.S. Revenue Opportunity in CINV

    Annual Market Potential (2014) Large U.S. Revenue Opportunity in CINV Source: IMS claims data, Company estimates 5M admins of emetogenic chemotherapy 4M 5-HT3 treatments 1M NK-1 RA admins ~20% ORAL ~80% IV U.S. Market Opportunity Exceeds $1 Billion VARUBI®: - 1,000,000.00 2,000,000.00 3,000,000.00 4

  18. Slide 18: The TESARO Field Organization

    The TESARO Field Organization: An Asset Offering Significant Leverage VARUBI®: Field Sales Organization Medical Science Liaisons Reimbursement Managers Account Managers Sales Training & Support Product Management & Marketing Approximately 120 Total Headcount Pharmacists Payers / PBMs GPOs / Distribu

  19. Slide 19: ~70% of Oncology Patients are Treated in the Community Setting

    ~70% of Oncology Patients are Treated in the Community Setting Patient Treatment IOD Clinics VARUBI®: Hospital Community Clinics IOD Non-IOD 40% of community based practices have in-office dispensing capabilities Large, sophisticated practices resulting in approximately 50% of oral cancer drug dispe

  20. Slide 20: HCP and Patient Perceptions of Delayed CINV Are Disconnected

    HCP and Patient Perceptions of Delayed CINV Are Disconnected HCP=healthcare provider 1. Grunberg SM et al. Cancer. 2004;100:261-268 A survey of physicians and nurses who were asked to estimate the frequency of acute and delayed CINV among patients in their own practices who received MEC1 Delayed CIN

  21. Slide 21: Variance From Practice Guidelines

    Variance From Practice Guidelines Two-thirds of Respondents Have Guidelines Within Their Practice That Dictate Antiemetic Prescribing *Respondents limited to those who indicated they have a practice formulary Source: Xcenda market research 90% of Oncologists Vary from Practice Guidelines <10% of the

  22. Slide 22: Top Factors Influencing Antiemetic Regimen Choice

    Evidence of Efficacy Practice Treatment Guidelines or Clinical Pathways Insurance Requirements Availability in My Practice What Are the Top Factors That Influence the Choice of Antiemetic Regimen? Source: Xcenda market research The Most Influential Factors in Selecting Antiemetic Therapy Are Efficac

  23. Slide 23: Improvement in Delayed CINV is Viewed as the Most Important Data Point

    Improvement in Delayed CINV is Viewed as the Most Important Data Point 84% of Respondents Felt the Data Demonstrating a Statistically Significant Improvement in Delayed CINV Was Sufficiently Encouraging to Lead Them to Use Product X Which Patients? (N=135) All Patients, if Reimbursement Was Assured

  24. Slide 24: Rolapitant IV Program Overview & Bioequivalence Study Results

    Rolapitant IV Program Overview & Bioequivalence Study Results

  25. Slide 25: Bioequivalence Demonstrated to Rolapitant Oral; NDA Submitted

    Bioequivalence Demonstrated to Rolapitant Oral; NDA Submitted Study Design Study Results Bioequivalence, determined by AUC0-t and AUC0- Safety, tolerability Endpoints 1:1 Randomization 200 mg Oral Rolapitant (n=62) 185 mg IV Rolapitant (n=61) 123 Healthy Volunteers Similar Exposure (AUC) for Oral an

  26. Slide 26: Niraparib

    Niraparib A Potentially Best-in-Class PARP Inhibitor in Phase 3 for Ovarian and Breast Cancers

  27. Slide 27: TESARO's Most Advanced Cancer Therapeutic Candidate

    TESARO’s Most Advanced Cancer Therapeutic Candidate Orally active, potent PARP 1/2 inhibitor Convenient, once daily dosing Compelling response rates and durations of response in highly pre-treated populations demonstrated in Phase 1 (N=100) Safety profile well characterized Clinical and genetic enri

  28. Slide 28: Niraparib Pipeline: A Portfolio of Opportunities

    Compound Therapeutic Area Discovery Pre- clinical Ph 1 Ph 2 Ph 3 Registration Niraparib 2L Ovarian Cancer (NOVA) Ovarian Cancer Treatment (QUADRA) 1L Ovarian Cancer (PRIMA) BRCA+ Breast Cancer (BRAVO) Niraparib + pembrolizumab Triple Negative Breast & Ovarian Cancers Niraparib + bevacizumab Ovarian

  29. Slide 29: Key Phase 1 Results

    Key Phase 1 Results HGSOC: High grade serous ovarian cancer. DLT: Dose limiting toxicity. Phase 1 RECIST Response Data Durable responses >1 year in platinum sensitive ovarian patients, regardless of gBRCAmut status 431 days in gBRCA+ patients 444 days in gBRCA- patients Heavily pre-treated patient p

  30. Slide 30: Considerations for Registration Studies

    Considerations for Registration Studies Ledermann J., et. al., N Engl J Med, 2012. Gelmon, Lancet Oncology, 2011. Tutt, Lancet, 2010. Ovarian Cancer BRCA+ Breast Cancer Patient Selection gBRCA+ Platinum sensitive gBRCA+ or gBRCA- gBRCA+ Standard of Care Watchful Waiting Chemotherapy Literature Indic

  31. Slide 31: NOVA Study Design and PFS Analysis

    Phase 3 NOVA Trial NOVA Study Design and PFS Analysis Prospectively defined statistical analysis of PFS in the HRD population >90% power PFS: Progression free survival; HRD: Homologous recombination deficiency gBRCAmut Endpoint Assessment Niraparib 300 mg Placebo Non-gBRCAmut / HRD Endpoint Assessme

  32. Slide 32: NOVA Trial Process to Analyze PFS Events

    Phase 3 NOVA Trial Process to Analyze PFS Events Prospectively defined statistical analysis of PFS in the HRD population >90% power PFS: Progression free survival; HRD: Homologous recombination deficiency gBRCAmut Endpoint Assessment Niraparib 300 mg Placebo Non-gBRCAmut / HRD Endpoint Assessment Ni

  33. Slide 33: Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions

    Median PFS in chemotherapy-free maintenance period is < 6 months Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions *Maintenance Period initiates ~6w post discontinuation of chemotherapy (6 x 21day cycles) Source: ICON4, CALYPSO, AGO-OVAR 2.5 and OCEANS trials. Ad

  34. Slide 34: NOVA Assumptions: Control Arm

    NOVA Assumptions: Control Arm *PFS: time from randomization; TTP: Time to progression from end of chemotherapy Reference Responders at start of maintenance PFS/TTP* post discontinuation of chemotherapy (control arm) Switch Maintenance (6 cycles of chemotherapy (CR/PR), followed by maintenance) Carbo

  35. Slide 35: History of NOVA Phase 3 Trial

    History of NOVA Phase 3 NOVA Trial Prospectively defined statistical analysis of PFS in the HRD population >90% power PFS: Progression free survival; HRD: Homologous recombination deficiency gBRCAmut Endpoint Assessment Niraparib 300 mg Placebo Non-gBRCAmut / HRD Endpoint Assessment Niraparib 300 mg

  36. Slide 36: myChoice HRD Test

    myChoice® HRD MyChoice® HRD Test Xenograft data presented at ASCO 2015. Combined Studies Ovarian HRD- population Non responders (PDX) HRD+ population Responders (PDX) HRD score is derived from a SNP based chromosome analysis of tumor tissue The HRD score is the sum of 3 scores, each derived from an

  37. Slide 37: BRCA and Homologous Recombination Deficiency

    BRCA is critical to DNA repair through homologous recombination, a high fidelity repair process that is template directed Loss of BRCA function is associated with genomic scarring through Homologous recombination deficiency (HRD) and low fidelity DNA repair Beyond BRCA: The Use of Homologous Recombi

  38. Slide 38: HRD Scoring of Breast and Ovarian Patient-Derived Xenografts

    HRD Scoring of Breast and Ovarian Patient-Derived Xenografts HRD score BRCA wt BRCA1 mut BRCA2 mut BRCA1 met Resistant to niraparib Sensitive to niraparib Data presented at ASCO 2015. Established HRD Score of 42 Identifies Niraparib Sensitive and Resistant Tumors; Equivalent Response Rates Observed

  39. Slide 39: myChoice HRD Testing of NOVA Samples

    >80% of NOVA Tumor Samples Tested MyChoice® HRD Testing of NOVA Samples NIRAPARIB: ~50% of Patients in the Non-gBRCAmut Cohort are HRD+ 0 5 10 15 20 25 30 35 40 0-5 6-10 11-15 16-20 21-25 26-30 31-35 36-41 42-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80 81-85 86-90 91-95 BRCAmut HRD+BRCAwt HRD-BRCAw

  40. Slide 40: Building an Ovarian Cancer Franchise

    Building an Ovarian Cancer Franchise PFS: Progression free survival ORR: Overall response rate HRD: Homologous recombination deficiency PFS primary endpoint Efficacy analyses in prespecified gBRCAmut and non-gBRCA / HRD+ patients Data expected in Q2 2016 2nd Line (Recurrent) Ovarian NOVA Trial ORR p

  41. Slide 41: Registration Trial of Niraparib for Ovarian Cancer (QUADRA)

    Endpoint Assessment Niraparib 300 mg Daily Treatment Received 3 or More Lines of Chemotherapy N=225 Registration Trial of Niraparib for Treatment of Ovarian Cancer (QUADRA Trial) High Grade Serous Ovarian Cancer, Platinum Resistant or Platinum Sensitive, gBRCAmut or HRD Overall Response Rate (ORR) P

  42. Slide 42: Phase 3 Trial of Niraparib in 1st Line Ovarian Cancer (PRIMA)

    Niraparib N=192 Placebo N=96 Tumor Biomarker Positive Ovarian Cancer 2:1 Randomization Phase 3 Trial of Niraparib in 1st Line Ovarian Cancer (PRIMA Trial) *Control from ICON 7, OVAR 16 and erlotinib studies. Responded to 1st Line Platinum Chemotherapy, with No Evidence of Progression, No Disease >2c

  43. Slide 43: Peak PARP Inhibitor Market Opportunity in Ovarian Cancer Approximates $4 Billion

    Peak PARP Inhibitor Market Opportunity in Ovarian Cancer Approximates $4 Billion 2L: 2nd Line; Treatment: 3 or more lines of previous therapy Dollar figures reflect current PARP inhibitor pricing. Source: Decision Resources; Company estimates gBRCAmut non-gBRCAmut / HRD+ Biomarker negative Eligible

  44. Slide 44: Breast Cancer: Phase 3 Treatment Trial Design (BRAVO)

    Breast Cancer: Phase 3 Treatment Trial Design (BRAVO Trial) PFS: Progression free survival. TNBC: Triple negative breast cancer. 2:1 Randomization 300 mg Niraparib Investigator Choice: Eribulin, Capecitabine, Gemcitabine or Vinorelbine PFS >95% power to detect 3 month improvement (HR 0.50) Assumptio

  45. Slide 45: Clinical Collaboration with Merck

    Clinical Collaboration with Merck KEYTRUDA® is a trademark of Merck & Co., Inc. Phase 1/2 trial of niraparib plus KEYTRUDA® (pembrolizumab) Goal to evaluate preliminary safety and efficacy of this combination Plan to enroll patients with triple-negative breast cancer or ovarian cancer Response rates

  46. Slide 46: Additional Monotherapy and Combination Trials

    Additional Monotherapy and Combination Trials QUADRA trial of niraparib for ovarian cancer treatment PRIMA trial of niraparib for first line ovarian cancer BRAVO trial of niraparib for patients with gBRCAmut advanced/metastatic breast cancer treatment Niraparib + bevacizumab (AVANOVA) combination fo

  47. Slide 47: Potential Value Proposition

    Potential Value Proposition 1 Compelling RECIST response rate and durability in heavily pre-treated patients 2 3 4 Broad development program in breast cancer 5 Biomarker incorporation potentially allows for patient selection 6 Potential for combinations with immuno-oncology and other targeted agents

  48. Slide 48: Immuno-Oncology Portfolio

    Immuno-Oncology Portfolio Monospecific Antibodies Targeting PD-1, TIM-3 and LAG-3 Plus Dual Specific Antibodies Targeting PD-1/TIM-3 and PD-1/LAG-3

  49. Slide 49: Advancing Our Early Stage I-O Pipeline

    Advancing Our Early Stage I-O Pipeline Compound Indication Discovery Pre- clinical Ph 1 Ph 2 Ph 3 Registration TSR-042 Anti-PD-1 mAb Various tumor types TSR-022 Anti-TIM-3 mAb Various tumor types Anti-LAG-3 mAb Various tumor types Anti-TIM-3/PD-1 dual reactive mAb Various tumor types Anti-LAG-3/PD-1

  50. Slide 50: TESARO's Vision & Strategy

    TESARO’s Vision & Strategy TESARO’s I-O portfolio: Three known checkpoint inhibitors PD-1, TIM-3 and LAG-3 Three bi-specific antibodies PD-1/TIM3 and PD-1/LAG-3 An additional, undisclosed bispecific Immune modulators are likely to treat many tumor types May be most effective when used in combination

  51. Slide 51: Immunotherapy Antibody Program

    Immunotherapy Antibody Program Webber ppt presentation. T cell PD-1 Negative Signal TIM3 LAG3 PD-1 Positive Signal TIM3 LAG3 Tumor/APC Tumor Death T cell Tumor PD-1, TIM-3 and LAG-3: checkpoint receptors expressed on T cells When triggered, they send a negative signal into the T cell Tumor survives

  52. Slide 52: Anti-TIM-3 Antibodies Enhance Activation of Human T cells

    Increased IL-2 Production in T Cell Activation Assay Anti-TIM-3 Antibodies Enhance Activation of Human T cells Anti-TIM-3 Lead 2.0 nM Anti-TIM-3 Back up 3.0 nM IgG Control EC50 IL-2 Concentration (pg/mL) mAb (nM) Immuno-Oncology: 0 500 1,000 1,500 2,000 0.01 0.1 1 10 100 1000

  53. Slide 53: Anti-TIM-3 Further Enhances Anti-PD-1 Activation of Human T Cells

    Increased IL-2 Production in Combination with Anti-PD-1 in MLR Assay Anti-TIM-3 Antibody Further Enhances Anti-PD-1 Activation of Human T Cells Anti-TIM-3 + 2 ng/ml anti-PD-1 0.93 nM Anti-TIM-3 + 20 ng/ml anti-PD-1 0.47 nM Anti-TIM-3 Lead 3.0 nM EC50 IL-2 Concentration (pg/mL) mAb (nM) Immuno-Oncolo

  54. Slide 54: Anti-LAG-3 Antibodies Enhance Activation of Human T Cells

    Increased IL-2 Production in MLR Assay Anti-LAG-3 Antibodies Enhance Activation of Human T Cells Anti-LAG-3 Lead 0.8nM Anti-LAG-3 Reference 6.0nM Anti-LAG-3 Reference 3.0nM EC50 IL-2 Concentration (pg/mL) mAb (nM) Immuno-Oncology: 0 500 1,000 1,500 2,000 0.1 1 10 100 1000

  55. Slide 55: Anti-LAG-3 Further Enhances Anti-PD-1 Activation of Human T cells

    Increased IL-2 Production in Combination with Anti-PD-1 in MLR Assay Anti-LAG-3 Antibody Further Enhances Anti-PD-1 Activation of Human T cells Anti-LAG-3 + 2 ng/ml anti-PD-1 200 pM Anti-LAG-3 + 20 ng/ml anti-PD-1 27 pM Anti-LAG-3 alone 800 pM EC50 mAb (nM) IL-2 Concentration (pg/mL) Immuno-Oncology

  56. Slide 56: Tumor Regression with Combination Anti-LAG3 and Anti-PD1

    Optimized Tumor Regression with Combination Anti-LAG3 and Anti-PD1 in the Colon26 Model = DOSING DAYS. Note: Each antibody dosed at 10mg/kg on days 4, 7, 11 and 14. PBS Anti-PD-1 Anti-LAG-3 Anti-LAG-3 + anti-PD-1 Tumor Re-challenge Day 85 Immuno-Oncology: 0 500 1000 1500 2000 0 5 10 15 20 25 30 35 4

  57. Slide 57: Tumor Regression with Combination Anti-TIM3 and Anti-PD1

    PBS Anti-TIM3 Anti-PD1 Anti-TIM3 + Anti-PD1 Optimized Tumor Regression with Combination Anti-TIM3 and Anti-PD1 in the MC38 Model = DOSING DAYS. Note: Each antibody dosed at 10mg/kg on days 1, 4, 8 and 11. Tumor Volume (mm3) Days Post Randomization Tumor Volume (mm3) Days Post Randomization Tumor Vol

  58. Slide 58: TSR-042: A Potent Anti-PD-1 Antibody

    Biacore Binding Kinetics to Human PD-1 TSR-042: A Potent Anti-PD-1 Antibody TSR-042 Backup KD 2.4 nM 6.7 nM PD-L1 or PD-L2 -DyL650 PD-1 CHO Ligand TSR-042 (IC50) Backup (IC50) PD-L1-DyL650 1.8 nM 2.1 nM PD-L2-DyL650 1.5 nM 1.8 nM TSR-042 Backup Blocks PD-L1 and PD-L2 Binding to PD-1 in a Competitive

  59. Slide 59: TSR-042 Enhances Activation of Human T cells

    Increased IL-2 Production in MLR Assay TSR-042 Enhances Activation of Human T cells IL-2 Concentration (pg/mL) TSR-042 67pM Backup 133pM Isotype Control EC50 mAb (nM) Immuno-Oncology: 0 500 1,000 1,500 2,000 No Antibody 0.001 0.01 0.1 1 10 100

  60. Slide 60: Assays for Functional Activity of Checkpoint Blockade

    Mixed Lymphocyte Reaction (MLR) CD4+ T Cells Stimulated With Allogeneic Monocyte-derived Dendritic Cells Assays for Functional Activity of Checkpoint Blockade Checkpoint Blockade Results in Increased T Cell Activation as Determined by IL-2 Production CD4 DC DC CD4 Donor A DCs PD-L1+TIM-3+MHCII+ Dono

  61. Slide 61: Advantages of the AnaptysBio Approach

    Advantages of the AnaptysBio Approach Mimicking the Natural Process for Eliciting an Antibody Response Under Controlled Conditions Generates Potent Human Antibodies Antibody Generation and Maturation via the Human Immune System Antibody Generation and Maturation via the SHM-XEL™ System Immuno-Oncolo

  62. Slide 62: Generating Antibodies with In Vitro Somatic Hypermutation

    Generating Antibodies with In Vitro Somatic Hypermutation SHM-XEL™ System for Ab Discovery & Optimization High throughput selection using FACs Starting Library Evolving Library More evolved Library Evolved Library Harnessing the natural mechanism of antibody maturation in vitro Ab genes have evolved

  63. Slide 63: Therapeutic Antibodies Controlled Selection for Optimal Therapeutic Properties

    Therapeutic Antibodies Controlled Selection for Optimal Therapeutic Properties AnaptysBio Technology Allows Selection for Optimal Properties and Circumvents the Need to Isolate Large Panels of Screening Antibodies Affinity To low pM KD values Functionality e.g., neutralization, signaling, apoptosis

  64. Slide 64: Near-Term Milestones

    Near-Term Milestones APC or Tumor Cell Exhausted T cell TCR Ag MHC PD-1 TIM-3 LAG-3 Activation signal Inhibitory signal Ag APC or Tumor Cell Reinvigorated T cell TCR MHC Activation signal Cytokines Effector mechanisms aPD-1 aLAG-3 aTIM-3 PD-1, LAG-3 and TIM-3 Are Key Immune Checkpoint Receptors That

  65. Slide 65: CORPORATE PRESENTATION March 2016

    CORPORATE PRESENTATION March 2016

  66. Slide 66: TESARO

    w TESARO CORPORATE PRESENTATION March 2016

TESARO — Investor Presentation (March 2016) on 6ix